{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:02:24Z","timestamp":1777420944314,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review data on efficacy and safety of dolutegravir (DTG) and lamivudine (3TC) in treatment-na\u00efve adults with HIV-1 infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>Phase III clinical trials and review articles were identified through PubMed (1996 to March 2020) and ClinicalTrials.gov (2000 to May 2020) using the keywords dolutegravir, lamivudine, and HIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Relevant clinical trials and review articles available in English evaluating efficacy and safety of DTG and 3TC were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>The once-daily, single-tablet regimen of DTG\/3TC is the first dual antiretroviral therapy (ART) recommended for initial therapy in treatment-na\u00efve adults with HIV-1 infection. DTG and 3TC were compared with a regimen of DTG and tenofovir disoproxil fumarate\/emtricitabine in the GEMINI studies and demonstrated noninferiority for the primary end point of virological suppression at up to 96 weeks. No treatment-emergent resistance mutations were identified in a small group of participants who did not reach virological suppression. The regimen is well tolerated, and the most common adverse events reported in trials include headache, diarrhea, nausea, insomnia, and fatigue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>This dual-ART regimen is a favorable treatment option for ART-na\u00efve patients with HIV-1 RNA &lt;500 000 copies\/mL, absence of hepatitis B virus, and no resistance to DTG or 3TC. Benefits of dual ART include reduction in treatment-related adverse events and toxicities, drug interactions, and cost. In addition, the once-daily, single-tablet formulation promotes adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>DTG\/3TC has demonstrated efficacy in maintaining virological suppression in ART-na\u00efve patients at up to 96 weeks while minimizing treatment-related adverse events and toxicities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1060028020933772","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T01:53:01Z","timestamp":1591753981000},"page":"1252-1259","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Na\u00efve Adults With HIV-1 Infection"],"prefix":"10.1177","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5239-8303","authenticated-orcid":false,"given":"Barbara A.","family":"Santevecchi","sequence":"first","affiliation":[{"name":"University of Florida, Gainesville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacy","family":"Miller","sequence":"additional","affiliation":[{"name":"University of Florida, Gainesville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5985-7979","authenticated-orcid":false,"given":"Lindsey M.","family":"Childs-Kean","sequence":"additional","affiliation":[{"name":"University of Florida, Gainesville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"key":"bibr1-1060028020933772","unstructured":"Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Accessed March 23, 2020. http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf"},{"key":"bibr2-1060028020933772","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S192735"},{"key":"bibr3-1060028020933772","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018793252"},{"key":"bibr4-1060028020933772","unstructured":"Juluca [package insert]. Research Triangle Park, NC: ViiV Healthcare; 2019."},{"key":"bibr5-1060028020933772","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30149-3"},{"key":"bibr6-1060028020933772","unstructured":"Dovato [package insert]. Research Triangle Park, NC: ViiV Healthcare; 2020."},{"key":"bibr7-1060028020933772","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.011008.145553"},{"key":"bibr8-1060028020933772","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1386"},{"key":"bibr9-1060028020933772","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00157-11"},{"key":"bibr10-1060028020933772","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001660"},{"key":"bibr11-1060028020933772","author":"Tivicay","year":"2020","journal-title":"ViiV Healthcare;"},{"key":"bibr12-1060028020933772","author":"Epivir","year":"2019","journal-title":"ViiV Healthcare;"},{"key":"bibr13-1060028020933772","volume-title":"Poster presented at: 20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs","author":"Gele T"},{"key":"bibr14-1060028020933772","unstructured":"Foisy M, Hughes C, Tseng A. Oral antiretroviral administration: information on crushing and liquid drug formulations. Accessed May 27, 2020. https:\/\/hivclinic.ca\/archive\/main\/drugs_extra_files\/Crushing%20and%20Liquid%20ARV%20Formulations.pdf"},{"key":"bibr15-1060028020933772","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy225"},{"key":"bibr16-1060028020933772","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.048918"},{"key":"bibr17-1060028020933772","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2019.1577821"},{"key":"bibr18-1060028020933772","doi-asserted-by":"publisher","DOI":"10.1177\/0956462417751961"},{"key":"bibr19-1060028020933772","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32462-0"},{"key":"bibr20-1060028020933772","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002275"},{"key":"bibr21-1060028020933772","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1243"},{"key":"bibr22-1060028020933772","unstructured":"ViiV Healthcare. Regimen switch to dolutegravir\/lamivudine fixed dose combination from current antiretroviral regimen in HIV-1 infected and virologically suppressed adults (SALSA). Accessed May 27, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04021290?term=SALSA&cond=Hiv&draw=2&rank=1"},{"key":"bibr23-1060028020933772","author":"Truvada","year":"2018","journal-title":"Gilead Sciences Inc;"},{"key":"bibr24-1060028020933772","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ296"},{"key":"bibr25-1060028020933772","unstructured":"ViiV Healthcare. ViiV healthcare submits supplemental new drug application to US FDA for use of Dovato in virologically suppressed adults with HIV-1. Accessed May 3, 2020. https:\/\/viivhealthcare.com\/en-gb\/media\/press-releases\/2019\/october\/viiv-healthcare-submits-supplemental-new-drug-application-to-us-\/"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020933772","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028020933772","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020933772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:37Z","timestamp":1777374937000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028020933772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1177\/1060028020933772"],"URL":"https:\/\/doi.org\/10.1177\/1060028020933772","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,9]]}}}